Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics | Synapse

February 11, 2022Open Access

Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics

SSSean C. SempleAcuitas Therapeutics (Canada)RLRobert D. LeoneBloomberg (United States)CBChristopher BarbosaAcuitas Therapeutics (Canada)

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

, a treatment for an otherwise fatal genetic disease called transthyretin amyloidosis. Lessons learned from the siRNA-LNP experience enabled the translation into the mRNA platform with the eventual authorization and approval of the mRNA-LNP vaccines against COVID-19. This marks the beginning of mRNA-LNP as a pharmaceutical option to treat genetic diseases.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Semple et al. (Fri,) studied this question.

synapsesocial.com/papers/69f2d8abddaa12f37bb3bd11 https://doi.org/https://doi.org/10.3390/pharmaceutics14020398